SCHEMBL2188595

SCHEMBL2188595

CC(C)([C@@H]1CCN(c2nc3ccccc3s2)C(=O)C1)S(=O)(=O)c1cccc(C(F)(F)F)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.43
CACNA1B Q00975 2/20 0.43
NR1I2 O75469 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.39
PCSK9 Q8NBP7 1/20 0.38
RAB9A P51151 3/20 0.38
KMT2A Q03164 4/20 0.38
TSHR P16473 2/20 0.37
NPSR1 Q6W5P4 2/20 0.37
NPC1 O15118 1/20 0.37
ALDH1A1 P00352 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.36
LMNA P02545 2/20 0.36
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2187131 1.00 CYP3A4 (0.43) CYP3A4CACNA1BNR1I2L3MBTL1PCSK9
SCHEMBL2187376 0.91 PCSK9 (0.38) CYP3A4CACNA1BNR1I2L3MBTL1PCSK9
SCHEMBL12415433 0.84 CACNA1B (0.44) CYP3A4CACNA1BNR1I2L3MBTL1KMT2A
SCHEMBL2190754 0.83 CACNA1B (0.43) CYP3A4CACNA1BNR1I2L3MBTL1KMT2A
SCHEMBL2188544 0.83 CACNA1B (0.43) CYP3A4CACNA1BNR1I2L3MBTL1KMT2A
SCHEMBL2189691 0.83 CACNA1B (0.45) CYP3A4CACNA1BNR1I2KMT2ATSHR
SCHEMBL2189149 0.83 CACNA1B (0.45) CYP3A4CACNA1BNR1I2KMT2ATSHR
SCHEMBL2190115 0.82 CACNA1B (0.47) CYP3A4CACNA1BNR1I2L3MBTL1KDM4E
SCHEMBL2188801 0.81 CACNA1B (0.49) CYP3A4CACNA1BNR1I2KMT2ATSHR
SCHEMBL2189252 0.80 CACNA1B (0.44) CYP3A4CACNA1BNR1I2L3MBTL1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS CHAKRAVARTY PRASUN K 2011-07-14 US claimed
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS CHAKRAVARTY PRASUN K 2011-07-14 US disclosed
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS CHAKRAVARTY PRASUN K 2011-07-14 US disclosed
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS CHAKRAVARTY PRASUN K 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS TRPV1, TRPA1, CACNA1D CYP3A4 939/4885CACNA1B 23/4885NR1I2 765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.